Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Infinity Pharmaceuticals Inc | INFI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0322 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0322 | 0.0322 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.0233 - 0.2597 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.0322 | USD |
Infinity Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 894.11k | 89.41M | - | 2.59M | -44.37M | -0.50 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Infinity Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/13/2023 | 07:11 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/12/2023 | 17:20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 9/11/2023 | 15:09 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/01/2023 | 15:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/10/2023 | 15:32 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/25/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/25/2023 | 15:05 | Business Wire | Infinity Pharmaceuticals Announces Value Preservation and.. |
| 7/24/2023 | 07:35 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/24/2023 | 07:30 | Business Wire | Infinity Pharmaceuticals Announces Termination of Merger.. |
| 7/14/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/14/2023 | 12:00 | Business Wire | Infinity Pharmaceuticals Announces Stockholder Approval of.. |
| 7/10/2023 | 07:30 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INFI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.1759 | 0.2597 | 0.0233 | 0.1244196 | 2,773,795 | -0.1437 | -81.69% |
| 3 Years | 3.35 | 3.89 | 0.0233 | 1.72 | 1,962,131 | -3.32 | -99.04% |
| 5 Years | 1.67 | 5.98 | 0.0233 | 2.04 | 1,435,773 | -1.64 | -98.07% |
Infinity Pharmaceuticals Description
| Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development. |
